Test

7-Year Follow-up of the POLARIX Study

Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 3

A BCMA-Directed Bispecific for the Treatment of Patients with R/R Multiple Myeloma After At Least 4 Prior Lines of Treatment

Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 1

For in-person participants only

A Therapy for Adults with RRMM After a PI and an Immunomodulatory Agent

Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 1

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Beyond a Single Biomarker: NGS Solutions for Hematologic Malignancies MRD Research

Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 4

For in-person participants only

Challenging the Status Quo in Thalassemia Management: Hear Patient Perspectives and Discover an Oral Treatment Option from Agios Pharmaceuticals

Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 4

For in-person participants only

This session will include a perspective from a patient living with thalassemia

Changing the ET Conversation: A New Paradigm in ET Management

Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 4

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

DARZALEX FASPRO + VRd: A Clinical Foundation from the CEPHEUS and PERSEUS Trials

Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - 291-292

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Discover A New Oral-Based Regimen for First Relapse Myeloma

Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Expanding Community Therapy Options in Relapsed or Refractory Multiple Myeloma: A BCMA-Targeted Option

Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 3

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

First-in-Class Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 5

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

From Data to Decisions: Advancing Patient Care in 2L+ Follicular Lymphoma and R/R DLBCL

Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Gene Addition Therapy in Sickle Cell Disease: Connecting Clinical Outcomes With the Patient Journey

Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 3

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

HYMPAVZI (marstacimab-hncq): Expanding Possibilities in Hemophilia Management and Case-Based Treatment Considerations

Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 2

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Indolent Mastocytosis: Evolving Perspectives on Treatment and Patient Impact

Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 5

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session includes a patient perspective

Insights into a RRMM Patient and Care Partner Journey: Clinical Evidence for a BCMA-Directed Therapy

Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 3

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session will include perspectives from a patient and caregiver

Learn About A Frontline Treatment Option in Peripheral T-Cell Lymphoma

Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - 288-290

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Let’s Talk About Hemophilia Management Today

Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 2

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

This session will include a patient perspective

OMISIRGE: Challenging Conventional Thinking About Time To Transplant And Patient Outcomes In Hematological Conditions With A Novel Cell Therapy Donor Source

Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 1

This presentation is intended for U.S. based registered meeting attendees

Ph+ CML-CP: A Nilotinib Treatment Option

Sunday, December 13, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 6

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Real-World Management of Hemophilia A and B: Clinical Cases with Rebalancing and Factor Replacement Therapies

Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 3

For in-person participants only

This session will include perspectives from patients living with Hemophilia A and B

See How Jaypirca (pirtobrutinib) is Sparking More Possibilities

Sunday, December 13, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 2

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

The APP Perspective: Building Confidence With DARZALEX Faspro

Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - 291-292

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

The Only BTKi Approved in 1L CLL/SLL and 1L MCL

Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 5

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Understanding Time off Treatment With an All-Oral, Fixed-Duration Regimen: Perspective of a Patient With Previously Untreated CLL

Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 2

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Understanding the Evolving Treatment Landscape of Relapsed/Refractory NPM1-mutated AML

Monday, December 14, 2026
8:00 a.m. - 9:00 a.m.
MCCNO - Hall J Theater 1

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

Unlocking the Potential for a Bispecific Antibody in 2L+ FL and 3L+ DLBCL

Monday, December 14, 2026
12:15 p.m. - 1:15 p.m.
MCCNO - Hall J Theater 2

This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

WAYRILZ (rilzabrutinib) Real World Cases & Patient Experience

Saturday, December 12, 2026
11:30 a.m. - 12:30 p.m.
MCCNO - Hall J Theater 4

For in-person participants only

This session will include a patient perspective